Drug Target Review

JANUARY 14, 2025

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech.

Drugs 69

Drugs Protein Expression Science Research 69

Drug Target Review

DECEMBER 6, 2024

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. For more: [link] ; [link] ; [link] ; [link] Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech.

RNA 52

RNA Drugs Research Science 52

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. As someone who describes himself as an “enthusiastic sceptic,” Wilkie is cautious but hopeful about the potential of AI in drug development. “I

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

Drug Target Review

FEBRUARY 14, 2025

The KEGG Pathway database provides insights into metabolic pathways, genetic interactions and disease mechanisms, which are crucial for understanding how a dataset can inform our understanding of complex biological phenomena such as signal transduction, cell proliferation, or immune responses.

Drugs 52

Drugs Research Immune Response Science 52

The Pharma Data

DECEMBER 15, 2020

Approval demonstrates our ability to execute upon the entirety of the drug development and registration process. About Actinic Keratosis Actinic keratosis or solar keratosis is a chronic and precancerous skin disease that occurs primarily in areas that have been exposed to ultraviolet (UV) radiation for a long period of time.

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

PLOS: DNA Science

OCTOBER 17, 2024

FDA approved a treatment for type 3 of the ultra-rare genetic disease September 20. The quest has been ongoing for three decades, said Laurie Turner, Family Services Manager of the National Niemann-Pick Disease Foundation. ” Miplyffa is the first drug developed to treat NPD3 specifically. million a year. In the U.S.,

Disease 52

Disease FDA Approval Drugs Treatment 52

The Pharma Data

APRIL 25, 2021

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Nirsevimab is an extended half-life RSV mAb being developed as a passive immunization for the prevention of LRTI caused by RSV. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.

Virus 40

Virus Trials Disease Hospitals 40